Pioneering translational immunotherapy for the treatment of patients with malignant brain tumors
The Duke Brain Tumor Immunotherapy Program (BTIP) has a singular, all-encompassing goal: develop novel, safe, and effective immune-based therapies for patients with brain tumors.
Our research projects are spearheaded by an outstanding complement of graduate students, medical students, residents, postdoctoral fellows, and junior and senior scientists assembled under the umbrella of the Duke BTIP. Duke neurosurgeon John H. Sampson, MD, PhD, is principal investigator.
The Duke BTIP combines the necessary funding support, intellectual and physical resources, and visionary leadership to meet its devoted objective of “pioneering translational immunotherapy” for the treatment of patients with malignant brain tumors. As a result, our program has offered brought more immunotherapies to trial for these patients than almost entity in the world.
In addition to the hope that we provide patients, we offer a unique opportunity for junior scientists and trainees to develop successful independent careers in science and translational medicine as they benefit from the wide array of resources, intellectual input, and clinical trials infrastructures of the Department of Neurosurgery, including the Brain Tumor Immunotherapy Program and the Preston Robert Tisch Brain Tumor Center at Duke.
Alex H. Sands Basic Sciences Research Building, Rm 221
Principal Investigator: John Sampson
Lab Manager: Sumie Okuwa
Duke University Medical Center
Durham, NC 27710